Vita Life Sciences : Full Year Results Presentation
February 22, 2022 at 10:29 pm
Share
ersonal use only
Financial Results
Year Ended 31 December 2021
VITA LIFE SCIENCES LTD
onlyuse
ersonalFINANCIAL RESULTS
Vita Life Sciences is an Australian owned healthcare company listed, on the Australian Securities Exchange (ASX:VLS).
Our core business is the development and distribution of over the counter (OTC) medicines, complementary and alternative medicines, dietary supplements and health foods throughout Australia, South East Asia and China.
With approximately 800 registered products, and over 400 employees, our philosophy is "thinking internationally, but acting locally". Our brands are Herbs of Gold and Vitahealth. We have teams of qualified naturopaths, nutritionists, biotechnologists and pharmacists formulating products that are of the highest standard, effective and functional.
| YEAR ENDED 31 DECEMBER 2021
2
FINANCIAL COMMENTARY
onlyuse
ersonalFINANCIAL RESULTS
Record Group sales of $57.1m, up 23% on previous corresponding period (PCP).
Record net profit of $8.2m, up 41%.
Trading performance reflects ongoing demand for complementary medicine across key markets.
Supply chain disruption mitigated through the deployment of risk mitigation strategies, including higher inventory holdings.
Balance sheet remains strong with equity of $30.4m and a net cash balance of $15.9m.
Earnings per share rising to 15.75 cents, up 36% on PCP.
Final dividend of 3.00 cents per share.
Full year dividend of 5.75 cents, up 35% on PCP.
| YEAR ENDED 31 DECEMBER 2021
A$'m
GROUP SALES
A$'m
GROUP EBIT
60
13
12
55
11
10
50
9
8
45
7
6
40
5
Full Year
Full Year
2021
2020
2021
2020
3
AUSTRALIAN OPERATION
ersonal use only
Record revenue of $30.3m an increase of 46% on PCP.
Penetration into the Pharmacy channel combined with strong growth from the Health Food channel drove underlying performance.
Increased education and training initiatives supported broader brand awareness and stronger retailer engagement.
Export sales predominantly to mainland China continued to gain traction. Increased exposure through all major e- commerce channels generated higher demand from consumers.
Higher sales, resulted in increased EBIT of 56%.
Revenue up 46%
A$'m
A$'m
35
6
30
5
25
4
20
15
3
10
2
Full Year
2021
2020
EBIT up 56%
Full Year 2021 2020
FINANCIAL RESULTS
| YEAR ENDED 31 DECEMBER 2021
4
EDUCATION & TRAINING
onlyuse
ersonalFINANCIAL RESULTS
| YEAR ENDED 31 DECEMBER 2021
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Vita Life Sciences Limited published this content on 23 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2022 03:28:04 UTC.
Vita Life Sciences Limited (Vita Life) is a pharmaceutical and healthcare company. The Company is involved in formulating, packaging, sales and distributing vitamins and supplements. Its core business is the development and distribution of over-the-counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. Its brand portfolio includes Herbs of Gold, VitaHealth, VitaScience and VitaLife. Herbs of Gold brand produces premium herbal, mineral, vitamin and superfood products. VitaHealth brand offers a comprehensive range of nutritional products that cater to every health need, from inner wellness to outer radiance. VitaScience is a vivacious nutritional supplement brand that offers practitioner strength quality formulations. Its subsidiaries include Vita Healthcare Asia Pacific Sdn Bhd, Herbs of Gold Sdn Bhd and others.
VITA LIFE SCIENCES LIMITED 
